Multiple sclerosis and Alzheimer's disease

Annals of Neurology

Volumn 63, Issue 2, 2008, Pages 174-183

  Dal Bianco, Assunta ^a   Bradl, Monika ^a   Frischer, Josa ^a   Kutzelnigg, Alexandra ^a   Jellinger, Kurt ^b   Lassmann, Hans ^a  

^a Medical University of Vienna   (Austria)

^b INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN CORTEX; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; INCIDENCE; LYMPHOCYTIC INFILTRATION; MALE; MENINX; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL; NEUROFIBRILLARY TANGLE; PLASMA CELL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; CEREBRAL ARTERIES; CHEMOTAXIS, LEUKOCYTE; COMORBIDITY; DISEASE PROGRESSION; ENCEPHALITIS; FEMALE; GLIOSIS; HUMANS; MALE; MENINGES; MICROGLIA; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEUROFIBRILLARY TANGLES; SENILE PLAQUES;

EID: 40449122005     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21240     Document Type: Article

References (51)

1. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
2. Meda L, Baron P, Prat E, et al. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25-35]. J Neuroimmunol 1999;93:45-52.
3. Lue LF, Walker DG, Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging 2001;22:945-956.
4. Walker DG, Link J, Lue LF, et al. Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol 2006;79:596-610.
5. Dickson DW, Lee SC, Mattiace LA, et al. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993;7:75-83.
6. McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:741-749.
7. Weisman D, Hakimian E, Ho GJ. Interleukins, inflammation, and mechanisms of Alzheimer's disease. Vitam Horm 2006;74: 505-530.
8. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
9. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448-452.
10. Wilcock DM, Munireddy SK, Rosenthal A, et al. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 2004;15: 11-20.
11. El Khoury J, Toft M, Hickman SE, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 2007;13:432-438.
12. Frenkel D, Maron R, Burt DS, Weiner HL. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest 2005;115:2423-2433.
13. Kidd D, Barkhof F, McConnell R, et al. Cortical lesions in multiple sclerosis. Brain 1999;122(pt 1):17-26.
14. Peterson JW, Bo L, Mork S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400.
15. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14:164-174.
16. Bo L, Vedeler CA, Nyland H, et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003;9:323-331.
17. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705-2712.
18. Wekerle H, Lassmann H. The immunology of inflammatory demyelinating disease. In: Compston A, Confavreux C, Lassmann H, eds. McAlpine's multiple sclerosis. Philadelphia: Churchill Livingstone, 2006:491-555.
19. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
20. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-259.
21. Jellinger KA. A view on early diagnosis of dementias from neuropathology. In: Herholz K, Morris C, Perani D, eds. The dementias: early diagnosis and evaluation. New York: Taylor & Francis, 2006:311-428.
22. Bruck W, Porada P, Poser S, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995;38:788-796.
23. Kutzelnigg A, Lassmann H. Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits? J Neurol Sci 2006; 245:123-126.
24. Giannakopoulos P, Hof PR, Mottier S, et al. Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathol (Berl) 1994;87: 456-468.
25. Bien CG, Bauer J, Deckwerth TL, et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol 2002;51:311-318.
26. Braak H, Braak E. Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder. Neurobiol Aging 1994;15: 355-356.
27. Taylor PR, Martinez-Pomares L, Stacey M, et al. Macrophage receptors and immune recognition. Annu Rev Immunol 2005; 23:901-944.
28. Unanue ER. Perspective on antigen processing and presentation. Immunol Rev 2002;185:86-102.
29. Martinez-Pomares L, Platt N, McKnight AJ, et al. Macrophage membrane molecules: markers of tissue differentiation and heterogeneity. Immunobiology 1996;195:407-416.
30. Polfliet MM, Fabriek BO, Daniels WP, et al. The rat macrophage scavenger receptor CD163: expression, regulation and role in inflammatory mediator production. Immunobiology 2006;211:419-425.
31. Huang Y, Yin H, Han J, et al. Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 2007;7:799-808.
32. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002;1:232-241.
33. Angata T, Kerr SC, Greaves DR, et al. Cloning and characterization of human Siglec-11. A recently evolved signaling that can interact with SHP-1 and SHP-2 and is expressed by tissue macrophages, including brain microglia. J Biol Chem 2002; 277:24466-24474.
34. Avril T, Attrill H, Zhang J, et al. Negative regulation of leucocyte functions by CD33-related siglecs. Biochem Soc Trans 2006;34:1024-1027.
35. Komohara Y, Hirahara J, Horikawa T, et al. AM-3K, an antimacrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem 2006;54:763-771.
36. Ahmed Z, Shaw G, Sharma VP, et al. The actin binding proteins Coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J Histochem Cytochem 2007;55: 687-700.
37. Deininger MH, Meyermann R, Schluesener HJ. The allograft inflammatory factor-1 family of proteins. FEBS Lett 2002;514: 115-121.
38. Payne J, Maher F, Simpson I, et al. Glucose transporter Glut 5 expression in microglial cells. Glia 1997;21:327-331.
39. McGeer EG, McGeer PL. Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. Mol Interv 2001;1:22-29.
40. Streit WJ, Mrak RE, Griffin WS. Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation 2004;1:14.
41. Town T, Nikolic V, Tan J. The microglial "activation" continuum: from innate to adaptive responses. J Neuroinflammation 2005;2:24.
42. Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci 2000;23: 618-625.
43. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991;30:694-700.
44. Storch MK, Piddlesden S, Haltia M, et al. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998;43:465-471.
45. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438.
46. Buee-Scherrer V, Buee L, Leveugle B, et al. Pathological tau proteins in postencephalitic parkinsonism: comparison with Alzheimer's disease and other neurodegenerative disorders. Ann Neurol 1997;42:356-359.
47. Yen SH, Horoupian DS, Terry RD. Immunocytochemical comparison of neurofibrillary tangles in senile dementia of Alzheimer type, progressive supranuclear palsy, and postencephalitic parkinsonism. Ann Neurol 1983;13:172-175.
48. Vercellino M, Plano F, Votta B, et al. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol 2005;64: 1101-1107.
49. Wegner C, Esiri MM, Chance SA, et al. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006; 67:960-967.
50. Kutzelnigg A, Faber-Rod JC, Bauer J, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 2007;17:38-44.
51. Streit WJ. Microglial senescence: does the brain's immune system have an expiration date? Trends Neurosci 2006;29: 506-510.